logo
  

BeiGene: FDA Defers Action On BLA For Tislelizumab Due To Travel Restrictions

BeiGene (BGNE) announced the FDA has deferred action on the Biologics License Application for tislelizumab as a second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma. The FDA is deferring action on the application as it has been unable to conduct required inspections in China due to COVID-19 related travel restrictions. In September 2021, the FDA accepted the BLA for tislelizumab and provided a PDUFA goal date of July 12, 2022.

BeiGene and Novartis will continue to work with the FDA to support scheduling the required inspections as soon as possible.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT